Top

Head and Neck Pathology

Published in:

18-08-2022 | Salivary Gland Cancer | Original Paper

Prognostic impact of MUC1 and potential regulatory miR-145 and miR-21 expression in salivary mucoepidermoid carcinoma

Authors: Ali Abdolrahmani, Neda Kardouni Khoozestani, Farid Azmoudeh-Ardalan, Ahmad Reza Shamshiri

Published in: Head and Neck Pathology | Issue 4/2022

Abstract

Background

Salivary gland mucoepidermoid carcinoma (MEC) poses a considerable risk of locoregional and distant metastasis after conventional treatments. There is an evident need for specifying prognostic biomarkers to identify patients who are in need of more intensive and prolonged follow-ups. This study aimed to assess the mucin 1 (MUC1) expression level and its potential regulatory microRNAs in salivary gland MEC and their prognostic potentials.

Materials and Methods

The expression of MUC1 in salivary gland MEC tissues was assessed in 47 samples using immunohistochemistry. Related microRNA (miR-145 and miR-21) were evaluated using quantitative Reverse Transcription PCR. The associations between MUC1 and microRNAs expressions and clinicopathological parameters were investigated.

Results

MUC1 expression levels positively correlated with histologic grade (p < 0.001), clinical stage (p = 0.04), risk of nodal metastasis (p = 0.02), as well as the likelihood of opting for radical treatment (p = 0.01). Increased expression of miR-21 (p < 0.001) and decreased expression of miR-145 (p < 0.001) were observed in MECs compared to normal salivary gland tissue. MiR-145 negatively (p = 0.01) and miR-21 positively (p = 0.01) correlated with MUC1 overexpression. Based on the univariate cox proportional hazard model, histologic grade and MUC1 expression level were significantly associated with disease-free, cancer-specific, and overall survival. However, the multivariable cox proportional hazard model indicated tumor grade as the only prognostic factor associated with disease-free survival.

Conclusion

Our results support the tumor suppressor role of miR-145 and the oncogenic role of miR-21 in salivary gland MEC. Also, MUC1 and miR-145 overexpression, as well as miR-21 suppression, show promising association with histologic tumor grade and clinical stage.

Available only for authorised users

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71(3):209–49. doi:https://doi.org/10.3322/caac.21660.CrossRef

Son E, Panwar A, Mosher CH, Lydiatt D. Cancers of the Major Salivary Gland. J Oncol Pract. 2018;14(2):99–108. doi:https://doi.org/10.1200/jop.2017.026856.CrossRef

Xu W, Hua Y, Deng F, Wang D, Wu Y, Zhang W, et al. MiR-145 in cancer therapy resistance and sensitivity: A comprehensive review. Cancer Sci. 2020;111(9):3122–31. doi:https://doi.org/10.1111/cas.14517.CrossRef

Robinson L, van Heerden MB, Ker-Fox JG, Hunter KD, van Heerden WFP. Expression of Mucins in Salivary Gland Mucoepidermoid Carcinoma. Head Neck Pathol. 2021;15(2):491–502. doi:https://doi.org/10.1007/s12105-020-01226-z.CrossRef

Ma J, Yang Y, Huo D, Wang Z, Zhai X, Chen J, et al. LincRNA-RoR/miR-145 promote invasion and metastasis in triple-negative breast cancer via targeting MUC1. Biochem Biophys Res Commun. 2018;500(3):614–20. doi:https://doi.org/10.1016/j.bbrc.2018.04.119.CrossRef

Supruniuk K, Radziejewska I. MUC1 is an oncoprotein with a significant role in apoptosis (Review). Int J Oncol. 2021;59(3). doi:https://doi.org/10.3892/ijo.2021.5248.

Zong ZH, Du YP, Guan X, Chen S, Zhao Y. CircWHSC1 promotes ovarian cancer progression by regulating MUC1 and hTERT through sponging miR-145 and miR-1182. J Exp Clin Cancer Res. 2019;38(1):437. doi:https://doi.org/10.1186/s13046-019-1437-z.CrossRef

Sachdeva M, Mo YY. MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Res. 2010;70(1):378–87. doi:https://doi.org/10.1158/0008-5472.Can-09-2021.CrossRef

Bahreyni A, Alibolandi M, Ramezani M, Sarafan Sadeghi A, Abnous K, Taghdisi SM. A novel MUC1 aptamer-modified PLGA-epirubicin-PβAE-antimir-21 nanocomplex platform for targeted co-delivery of anticancer agents in vitro and in vivo. Colloids Surf B Biointerfaces. 2019;175:231–8. doi:https://doi.org/10.1016/j.colsurfb.2018.12.006.CrossRef

10.

Denaro M, Navari E, Ugolini C, Seccia V, Donati V, Casani AP, et al. A microRNA signature for the differential diagnosis of salivary gland tumors. PLoS ONE. 2019;14(1):e0210968. doi:https://doi.org/10.1371/journal.pone.0210968.CrossRef

11.

Yang X, Wang X, Shen H, Deng R, Xue K. Combination of miR-21 with Circulating Tumor Cells Markers Improve Diagnostic Specificity of Metastatic Breast Cancer. Cell Biochem Biophys. 2015;73. doi:https://doi.org/10.1007/s12013-015-0573-0.

12.

Cinpolat O, Unal ZN, Ismi O, Gorur A, Unal M. Comparison of microRNA profiles between benign and malignant salivary gland tumors in tissue, blood and saliva samples: a prospective, case-control study. Braz J Otorhinolaryngol. 2017;83(3):276–84. doi:https://doi.org/10.1016/j.bjorl.2016.03.013.CrossRef

13.

Yan F, Wang C, Li T, Cai W, Sun J. Role of miR-21 in the growth and metastasis of human salivary adenoid cystic carcinoma. Mol Med Rep. 2018;17(3):4237–44. doi:https://doi.org/10.3892/mmr.2018.8381.CrossRef

14.

Brandwein MS, Ivanov K, Wallace DI, Hille JJ, Wang B, Fahmy A, et al. Mucoepidermoid carcinoma: a clinicopathologic study of 80 patients with special reference to histological grading. Am J Surg Pathol. 2001;25(7):835–45. doi:https://doi.org/10.1097/00000478-200107000-00001.CrossRef

15.

Lydiatt WM, Patel SG, O’Sullivan B, Brandwein MS, Ridge JA, Migliacci JC, et al. Head and neck cancers—major changes in the American Joint Committee on cancer eighth edition cancer staging manual. Cancer J Clin. 2017;67(2):122–37. doi:https://doi.org/10.3322/caac.21389.CrossRef

16.

Dos Santos ES, Normando AGC, Scarini JF, Crescencio LR, de Lima-Souza RA, Mariano FV, et al. Diagnostic and prognostic value of miRNAs on salivary gland tumors: a systematic review and meta-analysis. Oral Maxillofac Surg. 2021;25(4):445–56. doi:https://doi.org/10.1007/s10006-021-00952-0.CrossRef

17.

Roy LD, Sahraei M, Subramani DB, Besmer D, Nath S, Tinder TL, et al. MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition. Oncogene. 2011;30(12):1449–59. doi:https://doi.org/10.1038/onc.2010.526.CrossRef

18.

Mahomed F. Recent advances in mucin immunohistochemistry in salivary gland tumors and head and neck squamous cell carcinoma. Oral Oncol. 2011;47(9):797–803. doi:https://doi.org/10.1016/j.oraloncology.2011.06.008.CrossRef

19.

Handra-Luca A, Lamas G, Bertrand JC, Fouret P. MUC1, MUC2, MUC4, and MUC5AC expression in salivary gland mucoepidermoid carcinoma: diagnostic and prognostic implications. Am J Surg Pathol. 2005;29(7):881–9. doi:https://doi.org/10.1097/01.pas.0000159103.95360.e8.CrossRef

20.

Liu S, Ruan M, Li S, Wang L, Yang W. Increased expression of MUC1 predicts poor survival in salivary gland mucoepidermoid carcinoma. J Craniomaxillofac Surg. 2014;42(8):1891–6. doi:https://doi.org/10.1016/j.jcms.2014.07.008.CrossRef

21.

Alos L, Lujan B, Castillo M, Nadal A, Carreras M, Caballero M, et al. Expression of membrane-bound mucins (MUC1 and MUC4) and secreted mucins (MUC2, MUC5AC, MUC5B, MUC6 and MUC7) in mucoepidermoid carcinomas of salivary glands. Am J Surg Pathol. 2005;29(6):806–13. doi:https://doi.org/10.1097/01.pas.0000155856.84553.c9.CrossRef

22.

Siyi L, Shengwen L, Min R, Wenjun Y, Lizheng W, Chenping Z. Increased expression of MUC-1 has close relation with patient survivor in high-grade salivary gland mucoepidermoid carcinoma. J Oral Pathol Med. 2014;43(8):579–84. doi:https://doi.org/10.1111/jop.12170.CrossRef

23.

Shemirani N, Osipov V, Kolker A, Khampang P, Kerschner JE. Expression of mucin (MUC) genes in mucoepidermoid carcinoma. Laryngoscope. 2011;121(1):167–70. doi:https://doi.org/10.1002/lary.21164.CrossRef

24.

Rupaimoole R, Calin GA, Lopez-Berestein G, Sood AK. miRNA Deregulation in Cancer Cells and the Tumor Microenvironment. Cancer Discov. 2016;6(3):235–46. doi:https://doi.org/10.1158/2159-8290.Cd-15-0893.CrossRef

25.

Tang H, Li K, Zheng J, Dou X, Zhao Y, Wang L. microRNA-145 regulates tumor suppressor candidate 3 and mitogen-activated protein kinase pathway to inhibit the progression of colorectal cancer. J Cell Biochem. 2018. doi:https://doi.org/10.1002/jcb.28122.CrossRef

26.

Wu H, Xiao Z, Wang K, Liu W, Hao Q. MiR-145 is downregulated in human ovarian cancer and modulates cell growth and invasion by targeting p70S6K1 and MUC1. Biochem Biophys Res Commun. 2013;441(4):693–700. doi:https://doi.org/10.1016/j.bbrc.2013.10.053.CrossRef

27.

Jara D, Carvajal P, Castro I, Barrera M-J, Aguilera S, González S, et al. Type I Interferon Dependent hsa-miR-145-5p Downregulation Modulates MUC1 and TLR4 Overexpression in Salivary Glands From Sjögren’s Syndrome Patients. Front Immunol. 2021;12. doi:https://doi.org/10.3389/fimmu.2021.685837.

28.

Wang L, Wu X, Wang B, Wang Q, Han L. Mechanisms of miR-145 regulating invasion and metastasis of ovarian carcinoma. Am J Transl Res. 2017;9(7):3443–51.

29.

Ding J, Sun D, Xie P. Elevated microRNA-145 inhibits the development of oral squamous cell carcinoma through inactivating ERK/MAPK signaling pathway by down-regulating HOXA1. Biosci Rep. 2019;39(6). doi:https://doi.org/10.1042/bsr20182214.

30.

Shao Y, Qu Y, Dang S, Yao B, Ji M. MiR-145 inhibits oral squamous cell carcinoma (OSCC) cell growth by targeting c-Myc and Cdk6. Cancer Cell Int. 2013;13(1):51. doi:https://doi.org/10.1186/1475-2867-13-51.CrossRef

31.

Yu Y, Nangia-Makker P, Farhana L, Levi SGR, Majumdar E. AP. miR-21 and miR-145 cooperation in regulation of colon cancer stem cells. Mol Cancer. 2015;14:98. doi:https://doi.org/10.1186/s12943-015-0372-7.CrossRef

32.

Liu Q, Yang W, Luo Y, Hu S, Zhu L. Correlation between miR-21 and miR-145 and the incidence and prognosis of colorectal cancer. J buon. 2018;23(1):29–35.

Title: Prognostic impact of MUC1 and potential regulatory miR-145 and miR-21 expression in salivary mucoepidermoid carcinoma
Authors: Ali Abdolrahmani
Neda Kardouni Khoozestani
Farid Azmoudeh-Ardalan
Ahmad Reza Shamshiri
Publication date: 18-08-2022
Publisher: Springer US
Keywords: Salivary Gland Cancer
Metastasis
Salivary Gland Cancer
Published in: Head and Neck Pathology / Issue 4/2022
Electronic ISSN: 1936-0568
DOI: https://doi.org/10.1007/s12105-022-01475-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Prognostic impact of MUC1 and potential regulatory miR-145 and miR-21 expression in salivary mucoepidermoid carcinoma

Abstract

Background

Materials and Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Materials and Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2022

Keratoameloblastoma: A Report of Seven New Cases and Review of Literature

Human Papillomavirus-Associated Oral Cavity Squamous Cell Carcinoma: An Entity with Distinct Morphologic and Clinical Features

Immunohistochemical Expression Pattern of Theragnostic Targets SSTR2 and PSMA in Endolymphatic Sac Tumors: A Single Institution Case Series

MDM2 Gene Amplification and Expression of MDM2 and CDK4 are Rare in Ossifying Fibroma of Craniofacial Bones

Variability in Depth of Invasion Measurements in Carcinomas of the Oral Cavity and the Effect on Pathologic Tumor Staging

Peripheral Ossifying Fibroma and Peripheral Odontogenic Fibroma: Close Relatives or Family?